CO6511284A2 - Conjugados peg-lipido puros - Google Patents
Conjugados peg-lipido purosInfo
- Publication number
- CO6511284A2 CO6511284A2 CO11181678A CO11181678A CO6511284A2 CO 6511284 A2 CO6511284 A2 CO 6511284A2 CO 11181678 A CO11181678 A CO 11181678A CO 11181678 A CO11181678 A CO 11181678A CO 6511284 A2 CO6511284 A2 CO 6511284A2
- Authority
- CO
- Colombia
- Prior art keywords
- synthesis
- peg
- conjugates
- lipido
- glycerol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
- C08L63/10—Epoxy resins modified by unsaturated compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Abstract
Se divulga la síntesis del conjugado de polyethyleneglycol (PEG)-Iípido. Tal síntesis comprende los pasos de agregar oligómeros de PEG pequeños a la columna vertebral de glicerol hasta que se alcance la longitud deseada de la cadena. Los polímeros resultantes de esta síntesis están altamente mono dispersos. La presente invención provee varias ventajas tales como una síntesis simplificada, alto rendimiento de producto y bajo costo de los materiales de arranque. Es seguido el presente método de síntesis es adecuado para preparar un amplio rango de conjugados.En otro aspecto, la invención comprende conjugados PEG lípido teniendo una columna vertebral glicerol unidad de manera covalente a una o más cadenas PEG monodispersas y uno o más lípidos. Estos conjugados son especialmente útiles para formulaciones farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21762709P | 2009-06-02 | 2009-06-02 | |
US28406509P | 2009-12-12 | 2009-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6511284A2 true CO6511284A2 (es) | 2012-08-31 |
Family
ID=43298359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11181678A CO6511284A2 (es) | 2009-06-02 | 2011-12-30 | Conjugados peg-lipido puros |
Country Status (15)
Country | Link |
---|---|
US (1) | US20110040113A1 (es) |
EP (1) | EP2437756A2 (es) |
JP (1) | JP2012528857A (es) |
KR (1) | KR20120039564A (es) |
CN (1) | CN102665685A (es) |
AP (1) | AP2012006053A0 (es) |
AU (1) | AU2010257181A1 (es) |
BR (1) | BRPI1010175A2 (es) |
CA (1) | CA2763819A1 (es) |
CL (1) | CL2011003049A1 (es) |
CO (1) | CO6511284A2 (es) |
IL (1) | IL216719A0 (es) |
MX (1) | MX2011012823A (es) |
WO (1) | WO2010141069A2 (es) |
ZA (1) | ZA201109366B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
US20120202890A1 (en) | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
WO2012122144A1 (en) * | 2011-03-07 | 2012-09-13 | Wu Nian | Highly monodisperse branched peg-lipid conjugates |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
US8883177B2 (en) * | 2011-06-28 | 2014-11-11 | Nian Wu | Pharmaceutical compositions for parenteral administration |
US8575380B2 (en) * | 2011-10-17 | 2013-11-05 | Nof Corporation | Branched polyethylene glycol linked with diacyl glycerol, process for producing the same, and polyethylene glycol modified liposome |
KR102177437B1 (ko) * | 2012-08-21 | 2020-11-12 | 옵코 파마슈티칼스, 엘엘씨 | 리포좀 제제 |
US11458199B2 (en) | 2012-08-21 | 2022-10-04 | Opko Pharmaceuticals, Llc | Liposome formulations |
EP2887923B1 (en) | 2012-08-24 | 2023-04-05 | Sun Pharmaceutical Industries Limited | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions |
WO2015021044A1 (en) * | 2013-08-05 | 2015-02-12 | University Of Rochester | Compositions and methods for stimuli-responsive release of a therapeutic agent |
EP3077006B1 (en) * | 2013-12-05 | 2020-08-19 | Wu, Nian | Polymer-carbohydrate conjugates for drug delivery technology |
CA2929970C (en) | 2013-12-20 | 2020-05-12 | F. Hoffmann-La Roche Ag | Method of immobilizing a cell on a support using compounds comprising a polyethylene glycol moiety |
EP3084431B1 (en) * | 2013-12-20 | 2018-11-07 | Roche Diagnostics GmbH | Compounds comprising one or more hydrophobic domains and a hydrophilic domain comprising peg moieties, useful for binding cells |
WO2015091953A1 (en) * | 2013-12-20 | 2015-06-25 | Roche Diagnostics Gmbh | Use of compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising peg moieties for stabilization of a cell |
US9517270B2 (en) | 2014-12-08 | 2016-12-13 | The Board Of Regents Of The University Of Texas System | Lipocationic polymers and uses thereof |
US10064954B2 (en) | 2015-06-23 | 2018-09-04 | Nian Wu | Polymer-cyclodextrin-lipid conjugates |
KR20240027890A (ko) | 2015-09-14 | 2024-03-04 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 지질양이온성 덴드리머 및 이의 용도 |
CN106905120B (zh) * | 2015-12-21 | 2020-04-28 | 北京键凯科技股份有限公司 | Y型多缩乙二醇衍生物及其制备方法 |
US10918694B2 (en) | 2016-02-29 | 2021-02-16 | Sun Pharma Global Fze | Topical cyclosporine-containing formulations and uses thereof |
US10562849B2 (en) | 2016-05-16 | 2020-02-18 | The Board Of Regents Of The University Of Texas System | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids |
BR112018073671A2 (pt) | 2016-05-16 | 2019-02-26 | The Board Of Regents Of The University Of Texas System | composições para a entrega de rnat como nanopartículas e métodos de uso |
JP7216332B2 (ja) * | 2018-03-20 | 2023-02-01 | 日油株式会社 | 分岐型単分散ポリエチレングリコール、中間体およびその製造方法 |
WO2019189188A1 (ja) | 2018-03-29 | 2019-10-03 | 日油株式会社 | トリチル基含有単分散ポリエチレングリコールの精製方法 |
WO2019191597A1 (en) * | 2018-03-30 | 2019-10-03 | The Board Of Regents Of The University Of Oklahoma | Very long chain saturated fatty acid compounds, compositions containing same, and methods of use |
WO2020051223A1 (en) | 2018-09-04 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
GB2600800B (en) | 2018-09-04 | 2023-08-16 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
JP6805385B1 (ja) * | 2020-08-31 | 2020-12-23 | ジェイ−ネットワーク,インコーポレイテッド | 表皮内の保湿関連物質の発現増強剤 |
JP6860739B1 (ja) * | 2020-11-20 | 2021-04-21 | ジェイ−ネットワーク,インコーポレイテッド | 表皮内の抗酸化物質の発現増強剤 |
CN114685778B (zh) * | 2020-12-30 | 2023-10-17 | 苏州艾博生物科技有限公司 | 长循环阳离子脂质体的合成方法 |
CN117157101A (zh) | 2021-02-08 | 2023-12-01 | 德克萨斯大学系统董事会 | 不饱和的树枝状聚合物组合物、有关的制剂、及其使用方法 |
WO2023273364A1 (zh) | 2021-06-30 | 2023-01-05 | 天津键凯科技有限公司 | 聚乙二醇脂质及其应用 |
CN113461929B (zh) * | 2021-07-13 | 2023-04-21 | 浙江倍合德制药有限公司 | 一种tpgs系列产品的精制提纯方法 |
CN114507342B (zh) * | 2022-03-18 | 2024-03-19 | 江苏东南纳米材料有限公司 | 一种1,2-二肉豆蔻酰-rac-甘油-3-甲氧基聚乙二醇及其中间体的制备方法 |
WO2023196445A1 (en) * | 2022-04-05 | 2023-10-12 | Capstan Therapeutics, Inc. | Peg-lipids and lipid nanoparticles |
CN114524943B (zh) * | 2022-04-22 | 2022-09-16 | 天津凯莱英制药有限公司 | 聚乙二醇-甘油衍生物及其中间体各自的制备方法 |
WO2024105071A1 (en) * | 2022-11-15 | 2024-05-23 | Evonik Operations Gmbh | Polyoxyalkylene-1,2-dimyristoyl-glycerol compounds, wherein the polyoxyalkylene is a poly(ethylene oxide) having c1 to c3-alkyloxymethyl side chains |
CN116178733B (zh) * | 2023-03-03 | 2023-08-01 | 浙江博美生物技术有限公司 | 一种基于三官能团氨基酸的支化单分散peg衍生物、制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827533A (en) * | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
US7141552B2 (en) * | 2000-01-10 | 2006-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
AU2004272646B2 (en) * | 2003-09-15 | 2011-11-24 | Arbutus Biopharma Corporation | Polyethyleneglycol-modified lipid compounds and uses thereof |
US20060051405A1 (en) * | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
CA2629330C (en) * | 2004-11-12 | 2018-05-22 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
RU2010123882A (ru) * | 2007-11-14 | 2011-12-20 | Те Риджентс Оф Те Юниверсити Оф Калифорния (Us) | Модифицированные стеринами амфифильные липиды |
-
2010
- 2010-06-01 CN CN2010800303714A patent/CN102665685A/zh active Pending
- 2010-06-01 CA CA2763819A patent/CA2763819A1/en not_active Abandoned
- 2010-06-01 EP EP10783699A patent/EP2437756A2/en not_active Withdrawn
- 2010-06-01 MX MX2011012823A patent/MX2011012823A/es not_active Application Discontinuation
- 2010-06-01 BR BRPI1010175A patent/BRPI1010175A2/pt not_active Application Discontinuation
- 2010-06-01 WO PCT/US2010/001590 patent/WO2010141069A2/en active Application Filing
- 2010-06-01 KR KR1020117031713A patent/KR20120039564A/ko not_active Application Discontinuation
- 2010-06-01 US US12/802,197 patent/US20110040113A1/en not_active Abandoned
- 2010-06-01 AP AP2012006053A patent/AP2012006053A0/xx unknown
- 2010-06-01 AU AU2010257181A patent/AU2010257181A1/en not_active Abandoned
- 2010-06-01 JP JP2012513928A patent/JP2012528857A/ja active Pending
-
2011
- 2011-12-01 IL IL216719A patent/IL216719A0/en unknown
- 2011-12-02 CL CL2011003049A patent/CL2011003049A1/es unknown
- 2011-12-20 ZA ZA2011/09366A patent/ZA201109366B/en unknown
- 2011-12-30 CO CO11181678A patent/CO6511284A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2010141069A2 (en) | 2010-12-09 |
CA2763819A1 (en) | 2010-12-09 |
JP2012528857A (ja) | 2012-11-15 |
AP2012006053A0 (en) | 2012-02-29 |
EP2437756A2 (en) | 2012-04-11 |
BRPI1010175A2 (pt) | 2016-03-29 |
CL2011003049A1 (es) | 2012-07-13 |
AU2010257181A1 (en) | 2012-01-12 |
MX2011012823A (es) | 2012-06-25 |
ZA201109366B (en) | 2012-08-29 |
US20110040113A1 (en) | 2011-02-17 |
KR20120039564A (ko) | 2012-04-25 |
CN102665685A (zh) | 2012-09-12 |
WO2010141069A3 (en) | 2012-04-12 |
IL216719A0 (en) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6511284A2 (es) | Conjugados peg-lipido puros | |
CY1124769T1 (el) | Βελτιωμενο σκευασμα λιπιδιων | |
CY1121122T1 (el) | Πολυαιθυλενογλυκολιωμενα λιποσωματα για απελευθερωση rna που κωδικοποιει ανοσογονο | |
CU23556A1 (es) | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico | |
CY1117237T1 (el) | Συνθεσεις σταθερων τιακουμυκινων | |
CO6612199A2 (es) | Pèptidos tau antigènicos y usos de los mismos | |
CY1115999T1 (el) | Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη | |
CO6630147A2 (es) | Modificador del sabor dulce | |
BR112012013664A2 (pt) | rabdovírus oncolítico | |
CL2011000777A1 (es) | Compuestos derivados de imidazopiridazina, inhibidor de proteína quinasa; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, psoriasis, artritis reumatoide, angiogenesis, entre otras. | |
CY1119453T1 (el) | Λυοφιλοποιημενη παρασκευη κυτταροτοξικων διπεπτιδιων | |
CY1115354T1 (el) | Ενωσεις πεγκυλιωμενης ινσουλινης lispro | |
CO6361902A2 (es) | Composiciones de organogel y procesos para su producción | |
EA201201306A1 (ru) | Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка | |
AR078247A1 (es) | Vacuna de pcsk9 | |
MX344010B (es) | Conjugados de amatoxina con enlazantes mejorados. | |
MX2011009808A (es) | Agentes de elaboracion de imagen optica. | |
CO6571916A2 (es) | Derivados de arilmetoxi isoindolina y composiciones que lo comprenden y métodos para utilizar los mismos | |
BR112013017382A2 (pt) | métodos para preparação de glicoesfingolipídios e usos destes | |
CO6741152A2 (es) | Anticuerpos estables y solubles | |
AR092372A1 (es) | Formulaciones de liposomas, uso y metodo de tratamiento | |
UY31645A1 (es) | Nuevas imidazolidinas fenil-sustituidas, procedimiento para su preparación, medicamentos que conprenden dichos compuestos y su uso. | |
CU23792A3 (es) | Novedosos anticuerpos antiproliferación | |
EP2346537A4 (en) | LINEAR POLYESTERAMIDES OF AMINOPHENOLIC ESTERS | |
GT201200028A (es) | Derivados de amidas espirocíclicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |